Press Release: Eurofins Responds to Personal Care Industry Need for Residual Benzene Testing in Aerosol Products
14 November 2022
A great deal of media attention has been drawn to the personal care industry over the last several months, particularly highlighting aerosol can products containing trace benzene at 2 ppm or higher concentration. Benzene is a chemical solvent that becomes an environmental pollutant due to its release into the air. Benzene can have very harmful effects to humans and is carcinogenic.
With this growing industry concern, it is leading several aerosol product manufacturers to remove their products, including dry shampoo, body sprays, and non-stick cooking sprays, from their shelves and significantly impacts their overall brand and reputation and causes negative attention.
Eurofins is proud to announce that we offer testing capability for residual benzene on these personal care and food application aerosol products. Eurofins has demonstrated testing sensitivity as low as 180 parts per billion to detect these concentrations of benzene in these personal care products. Our laboratory contains state of the art Gas chromatography-mass spectrometry methods modified from USP<467> for detection and quantitation of benzene in a portfolio of aerosol products at concentration ranges from 200 ppb (parts per billion) to 2 ppm (parts per million).
To read the full press release, please visit: https://www.eurofinsus.com/food-testing/resources/eurofins-responds-to-personal-care-industry-need-for-residual-benzene-testing-in-aerosol-products/. For additional information on how we can provide your company with this testing, please contact ESFA_Projects@eurofinsUS.com, or call us as 1-262-754-5300.
For further information:
David Riggs
ir@eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a network of over 900 laboratories in 62 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
